Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Apr;33(4):679-682.
doi: 10.1038/s41433-019-0340-3. Epub 2019 Feb 12.

Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves' orbitopathy

Jonathan C P Roos  1   2 , Rachna Murthy  3   4   5
Affiliations
Case Reports

Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves' orbitopathy

Jonathan C P Roos et al. Eye (Lond). 2019 Apr.

Abstract

Background: Rapamycin (alternatively known as sirolimus) is a macrolide immunosuppressant commonly used for organ transplantation. It acts both on lymphocytes through the mechanistic target of rapamycin (mTOR) pathway to reduce their sensitivity to interleukin-2 (IL-2) and, importantly, also has anti-fibrotic properties by acting on myofibroblasts. The latter have been implicated in the pathogenesis of thyroid eye disease (TED).

Aim: To describe successful treatment and reversal of extraocular muscle fibrosis in TED with sirolimus.

Methods: Case report and literature review with clinic-pathological correlation.

Results: A patient with Graves' orbitopathy (GO) developed significant ocular motility restriction, which was unresponsive to steroids and conventional immunosuppression. Unlike these prior treatments, rapamycin therapy improved the diplopia and fields of binocular single vision over a period of months. There were no adverse effects directly attributable to the treatment.

Conclusion: With its low renal toxicity and ability to specifically target the underlying fibrotic pathways in GO, rapamycin may prove a useful adjunct to standard immunosuppressive regimes. We encourage further reporting of case series or the instigation of controlled trial.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

All authors are doctors who manage patients with thyroid eye disease. The authors declare that they have no conflict of interest.

As an anonymised retrospective report no institutional review board authorisation was necessary.

Dr. Murthy serves as guarantor of this work. It is an honest, accurate and transparent account of the study being reported; no important aspects of the study have been omitted.

Figures

Fig. 1
Fig. 1
Plot of field of binocular single vision (BSV) testing performed 2 weeks after starting sirolimus, on adopting an abnormal head posture (a). A small island of BSV subtending 4 quadrilaterals has appeared inferiorly indicated by the shaded area. b shows an increase in the area of BSV to 17 quadrilaterals, 8 months after starting sirolimus and performed with a reduced chin up head posture. c Fifteen months after the start of treatment, the BSV has increased to 46 quadrilaterals and the test was performed without a compensating head posture. d The effect persists even after cessation of treatment, seen here 3 years later with a BSV subtending 63 quadrilaterals
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhang L, Grennan-Jones F, Lane C, Rees DA, Dayan CM, Ludgate M. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:653–62. doi: 10.1210/jc.2011-1299. - DOI - PubMed
    1. Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, Llatjós R, Escobar I, Sala-Llinas E, et al. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulm Med. 2018;18:63. doi: 10.1186/s12890-018-0626-4. - DOI - PMC - PubMed
    1. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves’ disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002;168:942–50. doi: 10.4049/jimmunol.168.2.942. - DOI - PubMed
    1. Hillel AT, Gelbard A. Unleashing rapamycin in fibrosis. Oncotarget. 2015;6:15722–3. doi: 10.18632/oncotarget.4652. - DOI - PMC - PubMed
    1. Ghosh A, Malaisrie N, Leahy KP, Singhal S, Einhorn E, Howlett P, et al. Cellular adaptive inflammation mediates airway granulation in a murine model of subglottic stenosis. Otolaryngol Head Neck Surg. 2011;144:927–33. doi: 10.1177/0194599810397750. - DOI - PubMed

Publication types